Corporate and R&D Highlights
Executes Service Agreement with FyoniBio GmbH to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
Management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company's lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b, First-In-Human (FIH) study in advanced cancer patients suffering from solid tumors.
Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
A multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. The collaboration involves the evaluation of a senescence-modulating (i.e., anti-aging) compound to mitigate senescence and to complete experiments to further support the claims of recently filed fibrosis and cancer related patent applications, requested by Propanc Biopharma Inc. to the research group "Biological Technologies of The University of Jaén" and UGR's Research Group, "Advanced Therapies: Differentiation, Regeneration and Cancer."
Corporate and Financial Updates
Propanc entered into a private placement agreement for up to $100 million to accelerate clinical development. The Company received an initial $1,000,000 investment upon issuance of 100 shares of Series C Convertible Preferred Stock. As of March 31st, a further $1,000,000 investment was received upon exercise of 100 shares of Series C Convertible Preferred Stock.
Q3 Financial Summary (Quarter Ended March 31, 2026)
Total assets: $14.33 million
Total liabilities reduced by $2.10 million
Convertible notes reduced to $55,000 (from $538,000)
Net cash from financing activities: $4.47 million
Quarter-end cash: $443,702
$0.5 million tranche from the Series C facility subsequently received
The Company expects the financing facility to continually support planned R&D activities, including advancement of PRP and Rec-PRP.
Management Commentary
"We are entering a pivotal phase of development for the Company's lead asset, PRP, which is progressing to a world first, Phase 1b, First-In-Human study, in 30, 40 advanced cancer patients suffering from solid tumors. Execution of an agreement with Fyoni Bio will facilitate method development and validation of the pharmacokinetics method in preparation for the pivotal clinical study. In addition, management is engaging with CDMOs (Contract Development and Manufacturing Organizations) for the GMP manufacture of PRP for supply of the finished drug product, CROs (Clinical Research Organizations) to discuss management of future clinical trial operations, as well as preparing regulatory documentation for the Clinical Trial Application targeting submission later this year," said Mr. James Nathanielsz, Propanc's Chief Executive Officer. "Additionally, our multi-year research agreement with the Universities of Jaén and Granada will continue to support, strengthen and grow our intellectual property around the use of proenzymes not just in cancer, but also focusing on cell rejuvenation to overcome age-related, chronic diseases, such as fibrosis. I am confident we are on the right path to execute a rapid transformation of our Company to clinical stage for a range of incurable diseases which can offer renewed hope for patients."
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (NASDAQ:PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company's lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under "Risk Factors" in the prospectus related to the proposed offering and those described in the Company's filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:Propanc Biopharma, Inc.James Nathanielsz+61-3-9882-0780[email protected]
Investor Contact:[email protected]
PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, 2026
June 30, 2025
(Unaudited)
ASSETS
CURRENT ASSETS:
Cash
$
443,702
$
12,088
GST tax receivable
11,057
5,302
Prepaid expenses - current portion
7,733,625
8,334,046
Other current assets
35,104
1,380
TOTAL CURRENT ASSETS
8,223,488
8,352,816
Deferred offering costs
-
291,773
Prepaid expenses - long-term portion
6,057,422
10,925,835
Security deposit - related party
2,065
1,971
Operating lease right-of-use assets, net - related party
46,584
59,413
Property and equipment, net
4,221
-
TOTAL ASSETS
$
14,333,780
$
19,631,808
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable
$
973,692
$
1,249,596
Accrued expenses and other payables
942,376
1,486,550
Accrued interest
123,181
190,795
Loans payable
-
65,280
Loans payable - related parties, net of discount
465,282
415,329
Notes payable, net of discount
-
543,312
Convertible notes, net of discounts and including put premiums
55,000
537,921
Operating lease liability - related party, current portion
23,324
17,664
Warrant liability
104,313
-
Embedded conversion option liabilities
50,273
403,892
Employee benefit liability
738,187
667,901
TOTAL CURRENT LIABILITIES
3,475,628
5,578,240
NON-CURRENT LIABILITIES:
Loan payable - long-term - related party, net of discount
-
105,627
Operating ...
